# US 2024/0002953 A1 · Method for detecting polynucleotide variations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002953 A1
- Document ID: US20240002953A1
- Status: Published application
- Kind: A1
- Application number: 18/335,453
- Filed: 2023-06-15
- Published: 2024-01-04
- Earliest claimed: 2020-12-15
- Assignees: AnchorDx Medical Co., Ltd.
- Applicants: AnchorDx Medical Co., Ltd.
- Inventors: Zhiwei CHEN; Jianbing FAN
- Web page: https://patentgrep.com/patent/US20240002953A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G06N 3/08: Learning methods
- G06N 5/01: Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
- G06N 20/00: Machine learning
- G06N 20/20: Ensemble learning
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 40/20: Supervised data analysis
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present invention relates to a method for detecting polynucleotide variations by putative methylation and hydroxymethylation surrogate markers. The method comprises the following steps of: 1) isolating a polynucleotide from a biological sample; 2) identifying and characterizing methylation and/or hydroxymethylation biomarkers; and 3) identifying relevant methylation and/or hydroxymethylation markers or building a model according to candidate markers to infer and/or determine the polynucleotide variations. As a non-invasive adjuvant diagnostic method for precision cancer medicine, the method for detecting polynucleotide variations of the present invention is particularly effective for the identification of surrogate biomarkers in blood. The detection of the polynucleotide variations in the present invention can be used in the detection, prediction, precise treatment or postoperative monitoring of diseases.

## Claims

### Claim 1

A method comprising:
(a) obtaining a polynucleotide from a biological sample;
(b) assaying the polynucleotide to detect methylation and/or hydroxymethylation biomarkers;
(c) using the detected methylation and/or hydroxymethylation biomarkers to train a machine learning model, wherein the machine learning model is configured to detect polynucleotide variations in the biological sample based at least in part on an analysis of methylation and/or hydroxymethylation biomarkers.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polynucleotide comprises deoxyribonucleic acid (DNA).

### Claim 3 (depends on 1)

The method of claim 1, wherein the polynucleotide comprises ribonucleic acid (RNA).

### Claim 4 (depends on 1)

The method of claim 1, wherein the polynucleotide variations comprise single-nucleotide variations (SNVs).

### Claim 5 (depends on 4)

The method of claim 4, wherein the SNVs correspond to a gene selected from the group consisting of AKT1, ALK, APC, AR, ARF, ARID1A, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND2, CCNE1, CDH1, CDK4, CDK6, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, ESR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, GATA3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, KRAS, MEK1, MEK2, ERK2, ERK1, MET, MLH1, MPL, MTOR, MYC, NF1, NFE2LE, NOTCH1, NPM1, NRAS, NTRK1, NTRK3, PDGFRA, PI3CA, PTEN, PTPN11, RAF1, RB1, RET, RHEB, RHOA, RIT1, ROS1, SMAD4, SMO, STK11, TERT, TP53, TSC1, VHL, and a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the polynucleotide variations comprise insertions and/or deletions (indels).

### Claim 7 (depends on 6)

The method of claim 6, wherein the indels correspond to a gene selected from the group consisting of ATM, APC, ARID1A, BRCA1, BRCA2, CDH1, CDKN2A, EGFR, ERBB2, GATA3, KIT, MET, MLH1, MTOR, NF1, PDGFRA, PTEN, RB1, SMAD4, STK11, TP53, TSC1, VHL, and a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polynucleotide variations comprise fusions.

### Claim 9 (depends on 8)

The method of claim 8, wherein the fusions correspond to a gene selected from the group consisting of ALK, FGFR2, FGFR3, NTRK1, RET, ROS1, EML4, and a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the polynucleotide variations comprise copy number variations (CNVs).

### Claim 11 (depends on 10)

The method of claim 10, wherein the CNVs correspond to a gene selected from the group consisting of AR, BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2 (HER2), FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PI3CA, RAF1, and a combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the polynucleotide variations comprise an ERBB2 (HER2) gene amplification.

### Claim 13 (depends on 1)

The method of claim 1, wherein the biological sample comprises a biological fluid sample.

### Claim 14 (depends on 13)

The method of claim 13, wherein the biological fluid sample comprises blood, serum, plasma, vitreous body, sputum, urine, tear, sweat, or saliva.

### Claim 15 (depends on 1)

The method of claim 1, wherein the biological sample comprises a tissue sample.

### Claim 16 (depends on 1)

The method of claim 1, wherein the biological sample comprises a cell sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cell sample comprises a cell line sample.

### Claim 18 (depends on 1)

The method of claim 1, wherein (a) comprises isolating the polynucleotide from the biological sample.

### Claim 19 (depends on 18)

The method of claim 18, wherein the isolating comprises phenol-based and/or chloroform-based DNA extraction, magnetic bead isolation, or silica gel column isolation.

### Claim 20 (depends on 1)

The method of claim 1, wherein (b) comprises performing a chemical conversion or enzymatic conversion.

### Claim 21 (depends on 20)

The method of claim 20, wherein the chemical conversion comprises a bisulfite treatment.

### Claim 22 (depends on 20)

The method of claim 20, wherein the enzymatic conversion method comprises use of ten-eleven translocation (TET)- apolipoprotein B mRNA editing enzyme (APOBEC) or TET enzyme plus pyridine borane.

### Claim 23 (depends on 1)

The method of claim 1, wherein (b) comprises amplifying the polynucleotide.

### Claim 24 (depends on 23)

The method of claim 23, wherein the amplifying comprises polymerase chain reaction (PCR).

### Claim 25 (depends on 24)

The method of claim 24, wherein the PCR comprises methylation-specific PCR or a methylation-specific quantitative PCR (qPCR).

### Claim 26 (depends on 1)

The method of claim 1, wherein (b) comprises use of mass spectrometry.

### Claim 27 (depends on 26)

The method of claim 26, wherein the mass spectrometry comprises matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry.

### Claim 28 (depends on 1)

The method of claim 1, wherein (b) comprises use of microarray hybridization.

### Claim 29 (depends on 1)

The method of claim 1, wherein (b) comprises sequencing the polynucleotide.

### Claim 30 (depends on 29)

The method of claim 29, wherein the sequencing comprises whole genome bisulfite sequencing or targeted methylation sequencing.

### Claim 31 (depends on 30)

The method of claim 30, wherein the whole genome bisulfite sequencing or the targeted methylation sequencing is performed in combination with bisulfite and/or enzymatic reagent treatment.

### Claim 32 (depends on 1)

The method of claim 1, wherein (c) comprises selecting at least a subset of the detected methylation and/or hydroxymethylation biomarkers to derive an algorithm.

### Claim 33 (depends on 32)

The method of claim 32, wherein the selecting comprises performing Statistical analysis, Spearman analysis or Pearson analysis.

### Claim 34 (depends on 1)

The method of claim 1, wherein the algorithm derivation uses machine learning modeling.

### Claim 35 (depends on 34)

The method of claim 34, wherein the machine learning model comprises a Random Forest, a LASSO regression, a Logistic Regression, or a deep-learning network.

### Claim 36 (depends on 1)

The method of claim 1, wherein (b) comprises performing a methylation-specific primer extension-based assay.
